Delving into the Latest Updates on Gila Therapeutics, Inc. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	2

排名前五的药物类型	数量

合成多肽	1
重组多肽	1

关联

2

项与 Gila Therapeutics, Inc. 相关的药物

GT-002(Gila)

靶点-

作用机制-

在研机构

Gila Therapeutics, Inc.初创企业

原研机构

Gila Therapeutics, Inc.初创企业

在研适应症

肥胖

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GT-003(Gila Therapeutics)

靶点-

作用机制-

在研机构

Gila Therapeutics, Inc.初创企业

原研机构

Gila Therapeutics, Inc.初创企业

在研适应症

糖尿病

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期-

2

项与 Gila Therapeutics, Inc. 相关的临床试验

NCT05110664

/ Unknown statusN/AIIT

A Double-blind, Cross-over, Placebo-controlled, Proof-of-concept Study Using Oral Peptide YY3-36 Solution to Investigate the Mechanistic Role of Lingual PYY in Regulating Appetite, Energy Intake and Food Preference in People With Overweight/Obesity

A double-blind, cross-over, placebo-controlled, proof-of-concept study using oral peptide YY3-36 solution to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity. The aim of this study is to investigate the mechanistic role of lingual PYY in regulating appetite, energy intake and food preference in people with overweight/obesity.

开始日期2022-02-01

申办/合作机构

University College London

[+1]

NCT03490786

/ Completed临床1期

A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.

Dose escalation study of GT-001

开始日期2017-07-16

申办/合作机构

Gila Therapeutics, Inc.初创企业

100 项与 Gila Therapeutics, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Gila Therapeutics, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Gila Therapeutics, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Gila Therapeutics, Inc. 相关的转化医学

登录后查看更多信息